NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced that Ron Najafi, Ph.D., Chairman and CEO, will present a corporate and clinical update at the BIO CEO & Investor Conference, held February 10 -11, 2014 in New York City. Dr. Najafi along with Tom Paulson, Chief Financial Officer, and David Stroman, Ph.D., Senior Vice President, Ophthalmology, from NovaBay, will be available to respond to questions and to participate in one-on-one meetings with investors attending the conference.
Event: BIO CEO & Investor Conference
Date: Monday, February 10, 2014
Time: 9:30 am ET
Place: New York City
To access the live audio webcast of this presentation, please log on through a link located in the News & Events section of NovaBay’s website at http://novabay.com/investors/events. A replay of the webcast will be available one hour after the conclusion of the live event.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of the global, topical anti-infective market with its Aganocide compounds, led by auriclosene. Auriclosene is a new chemical entity invented by NovaBay that has a broad spectrum of activity against bacteria, viruses and fungi. Aganocide compounds are based on the human body’s natural immune system and the molecules involved in combating infections. Bacterial resistance to Aganocides is highly unlikely, as demonstrated in published studies. Once pathogens penetrate the body’s primary defense, the next line of defense is provided by the white blood cells. NovaBay has focused on understanding these molecules generated by the white blood cells and finding ways, by chemical modification, to allow them to be developed as therapeutic products with the potential to treat a wide range of local, non-systemic infections. NovaBay believes that Aganocides will help reduce the rise of antibiotic resistance as they begin to supplant the usage of classic topical antibiotics.
Stay informed on NovaBay’s progress:
NovaBay Pharmaceuticals Contacts
Thomas J. Paulson
Chief Financial Officer
Contact T. Paulson
Director, Investor Relations and Corporate Communications
NovaBay Pharmaceuticals, Inc.
Contact A. Kapor